TL;DR
This study investigated the effectiveness and safety of two antiplatelet therapies, Ticagrelor and Clopidogrel, when used with Aspirin in elderly Chinese patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTO). While both drugs showed similar effectiveness in preventing major adverse cardiac events (MACE), Ticagrelor was associated with a higher incidence of bleeding, particularly after accounting for baseline clinical differences.
What Problem Does This Paper Address?
Coronary Chronic Total Occlusion (CTO) is a common finding in patients with coronary artery disease, and percutaneous coronary intervention (PCI) is a recommended treatment to improve their quality of life and survival. However, CTO patients often require intensive dual antiplatelet therapy (DAPT) after PCI to prevent stent thrombosis. This is particularly challenging in elderly patients (≥75 years) who are at a higher risk of bleeding. While DAPT is crucial, balancing the risks of ischemic events (like heart attack) and bleeding is paramount. Existing clinical trials have often excluded or underrepresented elderly CTO patients, leaving a gap in understanding the optimal DAPT strategy for this specific demographic, especially in the East Asian population, which may exhibit unique responses to these therapies.
Methods
This was a single-center, retrospective cohort study. The researchers retrospectively analyzed data from 504 elderly Chinese patients (≥75 years) who underwent elective PCI for CTO between December 2009 and May 2020 and received DAPT for up to 12 months. Patients were divided into two groups: one receiving Clopidogrel plus Aspirin, and the other receiving Ticagrelor plus Aspirin.
To account for potential differences in baseline characteristics between the groups, the researchers employed the Inverse Probability of Treatment Weighting (IPTW) model. This statistical technique helps to balance the groups, making the comparison of treatment effects more robust.
Effectiveness was measured by the incidence of Major Adverse Cardiac Events (MACE), defined as a composite of all-cause death, nonfatal myocardial infarction, and clinically driven revascularization. Safety was assessed by the incidence of bleeding events, categorized according to the Bleeding Academic Research Consortium (BARC) criteria.
Datasets
The study utilized data from 504 elderly Chinese patients (aged ≥75 years) who underwent PCI for CTO between December 2009 and May 2020. This retrospective dataset was collected from the Department of Cardiology at Xijing Hospital. No new benchmarks were introduced; the study relied on existing patient data.
Key Insights and Ideas
- The "East Asian Paradox" in Bleeding: The study reinforces the concept of an "East Asian paradox," where patients in this demographic may experience lower ischemic event rates but higher bleeding risks with antiplatelet therapies compared to other populations.
- Ticagrelor's Bleeding Risk in Elderly CTO Patients: While Ticagrelor is known for its potent antiplatelet effects, this study highlights that in elderly Chinese CTO patients, it carries a significantly higher risk of bleeding, even when baseline differences are statistically adjusted.
- Importance of Risk Stratification: The findings underscore the critical need to carefully consider individual patient bleeding risk when selecting DAPT, especially in vulnerable elderly populations with complex conditions like CTO.
Key Results
- Similar Effectiveness: After 12 months of follow-up, the incidence of MACE was similar between the Clopidogrel group (12.19%) and the Ticagrelor group (11.04%), with no statistically significant difference (P=0.763).
- Higher Bleeding Incidence with Ticagrelor: The overall bleeding rate was higher in the Ticagrelor group (13.64%) compared to the Clopidogrel group (9.38%), although this difference was not statistically significant in the initial analysis (P=0.205).
- IPTW Confirms Ticagrelor's Bleeding Risk: After balancing clinical characteristics using the IPTW model, Ticagrelor was found to have an adverse impact on reducing bleeding incidence, with an IPTW odds ratio of 1.81 (95% CI: 1.18-2.76, P=0.006). This suggests Ticagrelor significantly increases bleeding risk in this patient group.
- Baseline Differences: The study noted some baseline differences between the groups. The Clopidogrel group was older and had higher BMI, diastolic blood pressure, and HDL-C. Conversely, the Ticagrelor group had a higher percentage of hyperlipidemia, prior PCI, glucose, TG, and LDL-C.
Limitations and Future Work
The authors acknowledge several limitations:
- Single-Center Retrospective Design: This design inherently carries a risk of selection bias and methodological biases.
- Small Sample Size: The study involved a relatively small number of patients, which can limit the generalizability of the findings.
- Cardiovascular Death Not Separately Analyzed: The study did not specifically isolate and analyze cardiovascular death as a distinct endpoint.
- Unadjusted Effectiveness Endpoints: The analysis of effectiveness endpoints (nonfatal MI and clinically driven revascularization) was not fully adjusted for all potential confounding factors.
- Exclusion of Other Therapies: The study did not account for the use of other therapeutic agents like beta-blockers, nor did it evaluate major adverse effects of P2Y12 inhibitors beyond bleeding.
The authors suggest that further prospective, multi-center, and large-scale trials are necessary to definitively verify the effectiveness and safety of Ticagrelor and Clopidogrel in elderly CTO patients undergoing PCI. They also recommend a more detailed analysis of bleeding events and consideration of other clinical factors.
Summary updated